Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 3
Submit an article Journal homepage
111
Views
11
CrossRef citations to date
0
Altmetric
Drug Profile

The cost–effectiveness of risperidone long-acting injection in the treatment of schizophrenia

Pierre Chue Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada. [email protected]
&
James Chue Clinical Trials and Research Program, Edmonton, Alberta, Canada
Pages 259-269 | Published online: 09 Jan 2014

References

  • Lindström E, Eberhard J, Neovius M, Levander S. Costs of schizophrenia during 5 years. Acta Psychiatr. Scand. Suppl. 435, 33–40 (2007).
  • Wu EQ, Birnbaum HG, Shi L et al. The economic burden of schizophrenia in the United States in 2002. J. Clin. Psychiatry 66(9), 1122–1129 (2005).
  • Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr. Bull. 34(1), 173–180 (2008).
  • Gilmer TP, Dolder CR, Lacro JP et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry 161(4), 692–699 (2004).
  • Loosbrock DL, Zhao Z, Johnstone BM, Morris LS. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J. Ment. Health Policy Econ. 6(2), 67–75 (2003).
  • Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr. Med. Res. Opin. 23(10), 2305–2312 (2007).
  • Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L [corrected to Matalon L]. Depot antipsychotic drugs. Place in therapy. Drugs 47(5), 741–773 (1994).
  • Gerlach J. Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr. Scand. Suppl. 382, 28–32 (1994).
  • Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in ‘revolving door’ schizophrenic patients. J. Clin. Psychiatry 57(8), 337–345 (1996).
  • Chue P. Risperidone long-acting injection. In: Antipsychotic Long-acting Injections. Haddad P, Lambert T, Lauriello J (Eds). Oxford University Press, Oxford, UK, 93–130 (2011).
  • Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br. J. Psychiatry 184, 346–351 (2004).
  • Annemans L. Cost–effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us? Pharmacoeconomics 23(Suppl. 1), 1–2 (2005).
  • Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost–effectiveness models. Pharmacoeconomics 23(Suppl. 1), 3–16 (2005).
  • Bartkó G, Fehér L. [Pharmacoeconomic review of the use of injectable long-acting risperidone]. Neuropsychopharmacol. Hung. 7(4), 199–207 (2005).
  • Edwards NC, Locklear JC, Rupnow MF, Diamond RJ. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 23(Suppl. 1), 75–89 (2005).
  • Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. Cost–effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 23(3), 299–314 (2005).
  • Chue PS, Heeg B, Buskens E, van Hout BA. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 23(Suppl. 1), 62–74 (2005).
  • Heeg BM, Antunes J, Figueira ML et al. Cost–effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr. Med. Res. Opin. 24(2), 349–358 (2008).
  • Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 23(Suppl. 1), 49–61 (2005).
  • Baca E, Bobes J, Canas F et al. Cost–effectiveness analysis of long-acting injectable risperidone v. olanzapine and v. fluphenazine decanoate in treating schizophrenia. Rev. Esp. Econ. Salud. 4, 273–285 (2005).
  • Llorca PM, Miadi-Fargier H, Lançon C et al. [Cost–effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Encephale 31(2), 235–246 (2005).
  • De Graeve D, Smet A, Mehnert A et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost–effectiveness analysis. Pharmacoeconomics 23(Suppl. 1), 35–47 (2005).
  • Yang YK, Tarn YH, Tarn YH et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin. Neurosci. 59(4), 385–394 (2005).
  • Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P. Cost–effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health 12(Suppl. 3), S66–S69 (2009).
  • Hensen M, Heeg B, Löthgren M, van Hout B. Cost effectiveness of long-acting risperidone in Sweden. Appl. Health Econ. Health Policy 8(5), 327–341 (2010).
  • Chue P. Long-acting risperidone injection: efficacy, safety, and cost–effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr. Dis. Treat. 3(1), 13–39 (2007).
  • Knapp M. Schizophrenia costs and treatment cost–effectiveness. Acta Psychiatr. Scand. Suppl. 407, 15–18 (2000).
  • Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br. J. Psychiatry. Suppl. (25), 18–21 (1994).
  • Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 14(1), 97–133 (1998).
  • Heider D, Bernert S, König HH et al. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom – findings from the European Schizophrenia Cohort (EuroSC). Eur. Psychiatry 24(4), 216–224 (2009).
  • Chue P, Llorca P, Duchesne I et al. Hospitalisation rates in patients during long-term treatment with RLAI injection. J. Appl. Res. 5, 266−274 (2005).
  • Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol. Drug Saf. 13(11), 811–816 (2004).
  • Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E; StoRMi Study Group. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol. 20(3), 121–130 (2005).
  • Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int. J. Clin. Pharmacol. Ther. 46(1), 14–22 (2008).
  • Mohl A, Westlye K, Opjordsmoen S et al. Long-acting risperidone in stable patients with schizoaffective disorder. J. Psychopharmacol. (Oxford) 19(Suppl. 5), 22–31 (2005).
  • Parellada E, Andrezina R, Milanova V et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J. Psychopharmacol. (Oxford) 19(Suppl. 5), 5–14 (2005).
  • Ganesan S, McKenna M, Procyshyn R et al. Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: a retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada). Curr. Ther. Res. 68, 409–420 (2007).
  • Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr. Scand. 116(1), 36–46 (2007).
  • Kissling W, Glue P, Medori R, Simpson S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum. Psychopharmacol. 22(8), 505–513 (2007).
  • Chang HC, Tang CH, Tsai SJ, Yen FC, Su KP. Long-acting injectable risperidone and hospital readmission: a mirror-image study using a national claim-based database in Taiwan. J. Clin. Psychiatry 70(1), 141 (2009).
  • Taylor M, Currie A, Lloyd K, Price M, Peperell K. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J. Psychopharmacol. (Oxford) 22(2), 128–131 (2008).
  • Carswell C, Wheeler A, Vanderpyl J, Robinson E. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin. Drug Investig. 30(11), 777–787 (2010).
  • Nick B, Vauth R, Braendle D et al. Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable. Int. J. Psychiatry Clin. Pract. 10, 174–181 (2006).
  • Peuskens J, Olivares JM, Pecenak J et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr. Med. Res. Opin. 26(3), 501–509 (2010).
  • Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J. Clin. Psychiatry 65(8), 1076–1083 (2004).
  • Crivera C, DeSouza C, Kozma CM, Dirani RD, Mao L, Macfadden W. Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE). BMC Psychiatry 11, 168 (2011).
  • Apiquian R, Córdoba R, Louzã M. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr. Dis. Treat. 7, 19–26 (2010).
  • Lloyd K, Latif MA, Simpson S, Shrestha KL. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum. Psychopharmacol. 25(3), 243–252 (2010).
  • Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr. Scand. 114(1), 14–20 (2006).
  • Taylor D, Cornelius V. Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up. J. Psychopharmacol. (Oxford) 24(7), 995–999 (2010).
  • Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr. Scand. 120(2), 97–101 (2009).
  • Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS; e-STAR Study Group. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr. Med. Res. Opin. 25(9), 2197–2206 (2009).
  • Olivares JM, Rodriguez-Morales A, Diels J et al.; e-STAR Spanish Study Group. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur. Psychiatry 24(5), 287–296 (2009).
  • Beauclair L, Chue P, McCormick J et al. Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. J. Med. Econ. 10(4), 427–442 (2007).
  • Koczerginski D, Arshoff L. Hospital resource use by patients with schizophrenia: reduction after conversion from oral treatment to risperidone long-acting injection. Healthcare Q. 14(1), 82–87 (2011).
  • Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
  • Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr. Q. 80(4), 241–249 (2009).
  • Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in The Netherlands. Clin. Ther. 32(1), 108–118 (2010).
  • Dalton A, Lambert T, Schrover R, Hertel J, Smith DK. The cost associated with administering risperidone long-acting injections in the Australian community. BMC Health Serv. Res. 11, 236 (2011).
  • Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group. Cost–effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl. Health Econ. Health Policy 6(1), 41–53 (2008).
  • Ren XS, Crivera C, Sikirica M, Dirani R, Qian S, Kazis LE. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. J. Clin. Pharm. Ther. 36(3), 383–389 (2011).
  • Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur. J. Health Econ. 11(6), 585–594 (2010).
  • Lambert T, Olivares JM, Peuskens J et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann. Gen. Psychiatry 10, 10 (2011).
  • Fleischhacker WW, Eerdekens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 64(10), 1250–1257 (2003).
  • van Os J, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int. Clin. Psychopharmacol. 19(4), 229–232 (2004).
  • Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur. Psychiatry 19(4), 219–225 (2004).
  • Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int. J. Neuropsychopharmacol. 8(3), 427–438 (2005).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.